What type of study is this?

September 10, 2025Journal of Thrombosis and HaemostasisOpen Access

Management of recurrent venous thromboembolism during anticoagulant treatment in patients with cancer: a prospective cohort study

View Full Paper

Ask AI

Bookmark

The risk of a second recurrent venous thromboembolism was substantial in patients with cancer despite treatment.
At 3 months, 10% of patients experienced a second recurrence of venous thromboembolism, and 12% had clinically relevant bleeding.
This prospective cohort study involved 94 patients with cancer, emphasizing the need for effective management and vigilance during anticoagulant treatment.
Bleeding occurred frequently, regardless of treatment intensity, highlighting considerable challenges in managing anticoagulation in this population.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Prospective cohort study evaluates treatment strategies for venous thromboembolism in cancer patients, suggesting significant risks and management challenges.

Cite This Study

Lanting et al. (2025) studied this question.

synapsesocial.com/papers/68c18f329b7b07f3a06158f4 https://doi.org/10.1016/j.jtha.2025.08.022

View Full Paper

Ask AI

Bookmark

Implication

Prospective cohort study evaluates treatment strategies for venous thromboembolism in cancer patients, suggesting significant risks and management challenges.

Management of recurrent venous thromboembolism during anticoagulant treatment in patients with cancer: a prospective cohort study

Key Points

Discussion

Implication

Cite This Study

Management of recurrent venous thromboembolism during anticoagulant treatment in patients with cancer: a prospective cohort study

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider